Results of the NRG Oncology clinical trial NRG-HN002 indicated that the combination of intensity-modulated radiotherapy (IMRT) and cisplatin was able to meet acceptability criteria for progression-free survival (PFS) and ...
Sep 17, 2019
0
0
Many chemotherapy drugs kill cancer cells by severely damaging their DNA. However, some tumors can withstand this damage by relying on a DNA repair pathway that not only allows them to survive, but also introduces mutations ...
Jun 6, 2019
0
304
(HealthDay)—Taxane plus platinum regimens may be a reasonable alternative to doxorubicin plus cisplatin as postoperative adjuvant chemotherapy for endometrial cancer that carries a high risk for progression, according to ...
Mar 27, 2019
0
1
Yale School of Medicine researchers have found that the progression of acute kidney injury to chronic kidney disease (CKD) caused by use of the chemotherapy drug cisplatin is due to unresolved injury and sustained activation ...
Mar 27, 2019
0
1
NUS chemists have developed a novel ratiometric fluorescent probe for studying cellular activity of the clinically important anticancer drug cisplatin for next generation drug development.
Feb 19, 2019
0
6
A drug increasingly used in combination with radiotherapy to treat a type of cancer that forms in the tonsils or the base of the tongue is inferior to a previously favored option, according to a large, clinical trial led ...
Nov 16, 2018
0
8
A new study funded by Cancer Research UK and led by the University of Birmingham has found that the standard chemotherapy used to treat a specific type of throat cancer remains the most effective.
Nov 15, 2018
0
16
Combinations of radiation and chemotherapy drugs have been shown to cure HPV-related head and neck cancer with a high success rate. A new phase III trial has now determined that cisplatin chemotherapy, combined with radiation ...
Oct 22, 2018
0
1
Patients with human papilloma virus (HPV)-positive throat cancer should receive chemoradiotherapy rather than cetuximab with radiotherapy, according to late-breaking research reported at the ESMO 2018 Congress in Munich.
Oct 22, 2018
0
3
Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer(NSCLC), shows a randomised study comparing ...
Oct 22, 2018
0
1
